Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
for Glioblastoma, IDH-wildtype
Sites in Providence +6 more locations
Sponsor: Orbus Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT05879367·Phase 1·Recruiting·Listed May 2023